Streptomycetal antibiotic

Claim 1

A pharmaceutical composition for treating bacterial infections in humans and animals which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure wherein MM 17880 is a di-acid solid of the molecular formula C 11-14 H 18-25 O 8-11 N 2 S 2 which in the form of a substantially pure di-sodium salt has the following characteristics: (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infrared spectrum substantially as shown in FIG. 1; (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2; (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3; (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and (e) when mixed with ampicillin or amoxycillin, it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes, in combination with a pharmaceutically acceptable carrier.

Claim 12

A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof an antibacterially effective amount of a pharmaceutical composition which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure formula MM 17880 is a diacidic solid of the molecular weight C 11-14 H 18-25 O 8-11 N 2 S 2 which in the form of a substantially pure di-sodium salt has the following characteristics: (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infrared spectrum substantially as shown in FIG. 1; (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2; (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3; (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and (c) when mixed with ampicillin or amoxycillin, it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes, in combination with a pharmaceutically acceptable carrier.

Claim 13

A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof an antibacterially effective amount of a pharmaceutical composition which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure formula MM 17880 is a diacidic solid of the molecular weight C 11-14 H 18-25 O 8-11 N 2 S 2 which in the form of a substantially pure di-sodium salt has the following characteristics: (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infrared spectrum substantially as shown in FIG. 1; (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2; (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3; (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and (c) when mixed with ampicillin or amoxycillin, it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes, in combination with a pharmaceutically acceptable carrier.